IL1B and myocardial infarction: The CANTOS trial was a phase III trial designed to test the effect of canakinumab, an anti-IL-1β monoclonal antibody, on the reduction of the risk of subsequent myocardial infarction, non-fatal stroke, or cardiovascular death in patients with previous myocardial infarction and no history of malignancy [39].